NCT07198009View on ClinicalTrials.gov

2-HOBA Supplementation in People With Elevated Lipoprotein(a)

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

November 30, 2026

Conditions
HyperlipidemiaElevated Lp(a)
Interventions
DIETARY_SUPPLEMENT

2-HOBA (Hobamine)

Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine), a dietary supplement with Generally Recognized as Safe (GRAS) status. The study dose is 400 mg three times daily with meals for 6 weeks.

Trial Locations (1)

02914

Lipid Clinic at Brown University Health, Providence

All Listed Sponsors
lead

The Miriam Hospital

OTHER

NCT07198009 - 2-HOBA Supplementation in People With Elevated Lipoprotein(a) | Biotech Hunter | Biotech Hunter